VIDEO + ARTICLE:
New research puts prions in the dementia/depression spotlight. What are they? Can the role prions play explain the depressive-like behavior common in dementia? Is targeting dementia’s prions the key to new treatments for major depression?
Prions (Proteinaceous infectious particles) are proteins in which the complex molecular three-dimensional folding process has simply gone astray. For reasons not yet understood, the misfolding nature of prions is associated to their ability to sequester their normal counterparts and induce them to misfold as well. The ever-growing crowd of misfolded proteins form the aggregates seen in the brains of patients with neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases. Patients with these disorders manifest progressive neurological deterioration and clinical depression, among other symptoms.
Continued below video…
Although the misfolded counterparts have historically received all the attention, the spotlight is now on the native protein, namely the prion protein, which is the one that has not undergone misfolding. What role do the native proteins play? An interesting hypothesis is that these particles serve as a hub where some cellular components assemble. For instance, it has already been shown that the prion protein participates in events such as cell proliferation, differentiation and survival. Now a team led by Dr. Rafael Linden from the Institute of Biophysics Carlos Chagas Filho, at the Federal University of Rio de Janeiro, in Brazil, proposes that the prion protein plays a role in depression.
The discovery of antidepressant drugs in the 1950s led to the first biochemical hypothesis of depression, known as the monoamine hypothesis. This hypothesis proposes that an imbalance of certain brain chemicals is the key cause of depression. Research has investigated whether and to what degree the “reward and pleasure” chemical dopamine and, more recently, the “happiness” chemical serotonin, could be the neurotransmitters involved in the malady. However, the monoamine hypothesis does not seem to fully explain the complexity of human depression. Now a new study offers one more important key that may increase our understanding of the pathogenesis behind clinical depression and neurodegenerative disorders.
In an article entitled “Prion protein modulates monoaminergic systems and depressive-like behavior in mice” and published in the Journal of Biological Chemistry, the group shows that mice lacking normal prions show a depressive-like behavior similar to depression symptoms found in patients with Alzheimer’s and prion diseases, namely Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Sträussler-Scheinker syndrome, Fatal Familial Insomnia and kuru. Human prion diseases frequently show clinical symptoms such as depression, anxiety, and hallucinations, and the monoamine hypothesis has been called to explain such deficits.
The research conducted by the group shows that mice with no prion protein have increased levels of the receptors that bind to serotonin. Additionally, the levels of the enzyme that makes dopamine, and dopamine itself, are also higher in mice deprived of the prion protein. Interestingly, the study shows that although these animals have high levels of dopamine, they do not show the normal response that should occur when dopamine binds to its receptor, despite the fact that the levels of the receptor for dopamine are normal in these animals. According to Danielle Beckman, the first author of the paper “it is possible that the lack of interaction between dopamine and its receptor results from a desensitization of the receptor precisely because there is too much dopamine.”
Dopamine & Serotonin
Another important observation made by the group, and which supports the hypothesis that prions have a role in depression, is the fact that the prion protein is found in the same places in the cell as the dopamine and serotonin receptors. Additionally, the authors observed that the prion protein might bind to the dopamine receptor.
The group believes that in normal individuals, the prion protein works as a scaffold for multiple molecular interactions. When prion protein molecules are sequestered by their misfolded counterparts, they can no longer work as a scaffold for all these molecular interactions, which impairs the mechanisms evoked by the brain chemicals important for mood.
These findings open the door for future research considering the prion protein as a potential target in the development of treatments for major depression and related disorders.
EurekAlert! by Publicase Comunicação Científica
- Danielle Beckman, Luis E. Santos, Tatiana A. Americo, Jose H. Ledo, Fernando G. de Mello, Rafael Linden. Prion Protein Modulates Monoaminergic Systems and Depressive-like Behavior in Mice.Journal of Biological Chemistry, 2015; 290 (33): 20488 DOI:10.1074/jbc.M115.666156
The nutraceutical supplement CARNOSINE,probably can works as a SUPPORT THERAPY IN PRION DISEASES,as we can see bellow. CARNOSINE is a peroxinitrites scavenger, antiglycating agent, mild heavy metal chelator,that is candidate as a support therapy to different types of neurodegenerative diseases,related to glycation and to aggregation and misfolding proteins disorders , as happens with príon disease and Alzheimer disease, Parkinson disease,etc. 1) ARTICLE:“ZINC,COPPER,AND CARNOSINE ATTENUATE NEUROTOXICITY OF PRION FRAGMENT PRP106-126” , 2011,journal Metallomics author Kawahara : “CARNOSINE,SIGNIFICANTLY INHIBITED THE NEUROTOXICITY OF PRIONS PROTEIN.CARNOSINE MIGHT BECOME A THERAPEUTIC TREATMENTS FOR PRION DISEASES."
2) ARTICLE: “INVOLVEMENT OF TRACE ELEMENTS IN THE PATHOGENESIS OF PRION DISEASES , CURRENT PHARMACEUTICAL BIOTECHNOLOGY”,2014 , author Mizuno D: " CARNOSINE CAN BE A NEUROPROTECTIVE SUBSTANCE AGAINST PRION DISEASES"
3) Article :“CARNOSINE:A VERSATILE ANTIOXIDANT AND ANTIGLYCATING AGENT”, authors George Perry ,Mark Smith and colleagues,Journal Science of Aging Knowledge Environment in 2005:"CARNOSINE as a naturally Antioxidant and as a mild heavy metal chelator,anti-glycating agent,Inhibit formation of Advanced Glycation End Products(AGEs)"